查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004887

更年期热潮红市场：依产品类型、销售管道和年龄组别划分－2026-2032年全球市场预测

Menopausal Hot Flashes Market by Product Type, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，更年期热潮红市场价值将达到 92 亿美元，到 2026 年将成长至 98.5 亿美元，到 2032 年将达到 143.9 亿美元，年复合成长率为 6.59%。

主要市场统计数据
基准年 2025 92亿美元
预计年份：2026年 98.5亿美元
预测年份 2032 143.9亿美元
复合年增长率 (%) 6.59%

一个简洁、情境化的框架，将临床症状管理、治疗方法方案和商业性优先事项结合起来，以便所有相关人员做出明智的决策。

更年期热潮红仍然是临床和商业性持续存在的挑战，它交织着临床症状管理、患者生活品质以及不断发展的治疗创新。本执行摘要全面概述了当前形势，涵盖治疗方法、通路、人口统计因素、区域趋势以及影响药物获取和分销的监管和贸易环境。其目的是提供一个连贯的叙述，以支援产品开发、医学事务、商业策略和供应链规划等方面的策略决策。

临床实践、病人参与和分销生态系统的现代变革正在重新定义更年期症状的治疗策略和商业模式。

在病患期望、科学进步和医疗服务模式不断发展的推动下，更年期热潮红的管理格局正在改变。病患自主权的提升和数位化健康工具的运用正在改变症状的报告和管理方式，而新的临床证据也拓展了传统荷尔蒙疗法以外的有效干预选择。因此，临床医生越来越多地采用综合疗法，结合生活方式调整、辅助疗法和标靶非荷尔蒙药物治疗。

药品价格调整对药品采购、生产经济和分销通路定价趋势的综合影响，以及对供应连续性和准入策略的影响。

2025年的政策环境，特别是美国国内的关税趋势，对更年期保健品生产商和经销商的供应链、筹资策略和成本结构产生了一系列累积影响。活性成分、经皮和外用製剂专用成分以及进口植物基原料的关税调整改变了采购成本的计算方式，促使企业重新评估其供应商多元化策略，并探索近岸外包和替代采购方式以维持供应的连续性。

将治疗领域、多通路分销和年龄组患者群体连结起来的详细細項分析，能够制定精准的目标定位和产品策略。

精细的市场細項分析揭示了不同治疗领域、分销管道和人口统计群体之间的不同趋势，从而为产品定位和商业策略提供了直接的洞察。就产品类型而言，以黑升麻萃取物、当归根萃取物和异黄酮萃取物等植物性化合物为代表的辅助疗法，持续吸引寻求处方笺药和被视为天然疗法的患者，同时也面临临床证据差异和监管不力等挑战。荷尔蒙疗法仍然是许多患者的基础疗法，雌激素-黄体素组合药物、雌激素单药疗法和选择性雌激素受体调节（SERMs）各自具有不同的安全性特征和处方情况。雌激素疗法本身分为口服、外用和经皮给药途径，其中经皮给药因其可减少全身暴露和调整剂量而更受青睐。

区域趋势和主要区域的监管差异决定了治疗方法的采纳、分发策略和证据生成的优先事项。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的监管方式、处方实践和分销基础设施都产生了深远的影响，每个地区都具有独特的战略意义。在美洲，完善的临床指南和成熟的支付方环境为差异化的治疗定位铺平了道路，但区域间在医疗服务可及性和保险覆盖范围方面的差异，使得个性化的市场准入和患者支持计划成为必要。同时，欧洲、中东和非洲地区拥有广泛的管理体制和支付方模式，需要灵活的监管策略和弹性价格设定方式，以应对公共卫生优先事项并适应不同医疗保健系统的能力。

竞争格局洞察，重点在于临床严谨性、供应链灵活性以及透过与分销管道的伙伴关係的策略差异化。

更年期治疗市场的竞争格局由多家公司组成，包括老牌製药公司、专业生物技术公司、植物来源和辅助疗法生产商，以及数位化原生零售商和服务供应商。老牌製药公司凭藉其丰富的临床经验、广泛的监管能力和整合的供应链，在荷尔蒙和非荷尔蒙药物领域保持着稳固的地位。同时，小规模但富有创新精神的公司往往透过针对性的作用机制研究、提高耐受性或开发新型给药技术来脱颖而出。

高阶主管面临的策略和营运挑战是，如何协调临床证据、通路策略和供应链弹性，从而建立永续的竞争优势。

产业领导者应优先考虑整合证据产生、病人参与和供应链韧性的综合策略，以最大限度地发挥不断变化的临床和商业性趋势的潜力。首先，投资于针对特定剂量和分子的、旨在评估安全性、耐受性和患者报告结局 (PRO) 的靶向临床试验，从而提高处方集采纳率和临床医生接受度。同时，开发以患者为中心的支持项目，将医疗主导的护理与数位化追踪相结合，透过教育和症状追踪工具提高用药依从性和长期治疗效果。

一个强大的混合方法研究框架，整合了临床医生访谈、监管分析和供应链检验，从而得出引人注目的策略见解。

本分析的研究途径利用了多方面的定性和定量数据，并交叉引用了同行检验的临床文献、监管公告、供应链文件和相关人员访谈，以构建全面平衡的观点。主要研究包括对临床医生、药房经理和供应链负责人进行结构化访谈，以揭示真实的临床实践模式、通路的经济效益和营运限制。次要研究整合了权威的临床研究、指南更新和政策变化，以阐明治疗决策和安全考量的背景。

整合治疗方案、营运韧性和证据优先性，制定切实可行的蓝图，为相关人员。

总之，在现代社会，应对更年期热潮红需要采取多管齐下的策略，整合临床证据、以病人为中心的医疗服务以及稳健的商业运作。治疗方案包括辅助草药疗法、多种给药途径的成熟荷尔蒙疗法以及日益普及的非荷尔蒙药物疗法，每种疗法在安全性、依从性和通路适用性方面都有其自身的考虑。同时，政策变化和贸易趋势凸显了积极主动的供应链规划和灵活的筹资策略对于确保药物可近性和可预测性的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：更年期热潮红市场：依产品类型划分

  • 辅助疗法
    • 黑升麻
    • 安吉莉卡
    • 异黄酮
  • 荷尔蒙疗法
    • 雌激素-黄体素联合治疗
    • 雌激素疗法
      • 口服雌激素
      • 局部雌激素
      • 经皮雌激素
    • 选择性雌激素受体调节
  • 非荷尔蒙疗法
    • 可乐定
    • Gabapentin
    • SSRI
      • Fluoxetine
      • 帕罗西汀
      • 舍曲林

第九章：更年期热潮红市场：依通路划分

  • 诊所
  • 医院药房
    • 私立医院
    • 公立医院
  • 线上零售商
    • 企业网站
    • 电子商务平台

第十章：更年期热潮红市场：依年龄组别划分

  • 40-50岁
  • 51-60岁
  • 60岁或以上

第十一章 更年期热潮红市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 更年期热潮红市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：更年期热潮红市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国更年期热潮红市场

第十五章：中国更年期热潮红市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Besins Healthcare
  • Cipla Ltd.
  • Endoceutics Inc.
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Hisamitsu Pharmaceutical Co., Ltd.
  • Lupin Ltd.
  • Millendo Therapeutics, Inc.
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theramex Ltd.
  • Viatris Inc.
Product Code: MRR-742BD51814A1

The Menopausal Hot Flashes Market was valued at USD 9.20 billion in 2025 and is projected to grow to USD 9.85 billion in 2026, with a CAGR of 6.59%, reaching USD 14.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.20 billion
Estimated Year [2026] USD 9.85 billion
Forecast Year [2032] USD 14.39 billion
CAGR (%) 6.59%

Concise contextual framing that aligns clinical symptom management, therapeutic choices, and commercial priorities for informed decision-making across stakeholders

Menopausal hot flashes represent a persistent clinical and commercial challenge that intersects clinical symptom management, patient quality of life, and evolving therapeutic innovation. This executive summary synthesizes the contemporary landscape spanning therapeutic modalities, distribution pathways, demographic considerations, regional dynamics, and the regulatory and trade environment shaping access and adoption. The objective is to provide a coherent narrative that informs strategic decisions across product development, medical affairs, commercial strategy, and supply chain planning.

The narrative that follows places emphasis on both clinical relevance and market-facing implications, balancing patient-centered outcomes with pragmatic considerations for manufacturers, payers, and providers. It identifies how therapeutic choices-from complementary and hormonal approaches to a growing array of non-hormonal pharmacotherapies-align with patient preferences, safety considerations, and prescribing trends. Moreover, the summary highlights how distribution and demographic segmentation drive differentiated uptake and service delivery models.

By framing these elements in an integrated manner, the introduction prepares readers for deeper analysis of structural shifts, policy impacts, and actionable recommendations. The intent is to equip stakeholders with the contextual understanding required to prioritize investments, adapt commercialization plans, and engage meaningfully with clinicians and patient communities.

Contemporary shifts in clinical practice, patient engagement, and distribution ecosystems are converging to redefine therapeutic strategies and commercial models for menopausal symptom management

The landscape for managing menopausal hot flashes is undergoing transformative shifts driven by patient expectations, scientific advances, and evolving care delivery models. Patient empowerment and digital health tools have altered how symptoms are reported and managed, while new clinical evidence has expanded the spectrum of viable interventions beyond traditional hormonal therapies. As a result, clinicians are increasingly integrating multi-modal approaches that combine lifestyle interventions, complementary modalities, and targeted non-hormonal pharmacotherapies.

Concurrently, regulatory scrutiny and safety narratives have prompted more nuanced prescribing behavior, encouraging the use of individualized treatment plans that weigh benefits and risks with greater granularity. These changes are accompanied by supply chain reconfigurations and a surge in direct-to-patient distribution pathways, which shift competitive dynamics and raise expectations for convenience, transparency, and patient support services. The convergence of clinical, regulatory, and commercial vectors is therefore reshaping product life cycles, forcing manufacturers to adapt in real time and to prioritize evidence generation that demonstrates both efficacy and patient-centred value.

Taken together, these transformative shifts demand a strategic re-evaluation of innovation priorities and go-to-market approaches, emphasizing flexible delivery, robust patient engagement, and cross-functional alignment between clinical development, regulatory affairs, and commercial teams.

Comprehensive effects of tariff shifts on pharmaceutical sourcing, manufacturing economics, and channel pricing dynamics that influence supply continuity and access strategies

The policy environment in 2025, notably tariff developments within the United States, has introduced a range of cumulative effects that ripple through supply chains, procurement strategies, and cost structures for manufacturers and distributors serving menopausal health. Tariff adjustments on active pharmaceutical ingredients, specialty components for transdermal and topical formulations, and imported botanical raw materials have altered sourcing calculus, prompting firms to reassess supplier diversification and to explore nearshoring or secondary sourcing to maintain continuity of supply.

Furthermore, increased import duties have amplified the importance of cost containment initiatives, accelerating negotiations with contract manufacturers and incentivizing process improvements to offset incremental input costs. In parallel, distributors and clinics have had to revisit pricing differentials across channels, with implications for reimbursement discussions and patient access programs. While tariffs do not alter clinical efficacy or regulatory approvals, they influence commercial viability by changing total landed costs and may indirectly affect formulary positioning and the economics of promotional programs.

As a result, organizations are adopting a combination of tactical measures-such as renegotiated supplier contracts, inventory hedging, and greater transparency in cost-to-serve calculations-and strategic pathways, including technology-enabled supply chain visibility and supplier risk scoring. These responses aim to protect supply continuity and preserve margins while ensuring that therapeutic choice and patient access remain central to decision-making.

In-depth segmentation narrative connecting therapeutic categories, multi-channel distribution, and age-based patient cohorts to inform precision targeting and product strategy

A nuanced segmentation analysis reveals differentiated dynamics across therapeutic classes, channels, and demographic cohorts that directly inform product positioning and commercial tactics. When considering product type, complementary therapies such as botanical compounds-exemplified by extracts like black cohosh, dong quai, and isoflavones-continue to attract patients seeking non-prescription options and perceived natural remedies, but they also face variability in clinical evidence and regulatory scrutiny. Hormonal therapies remain a cornerstone for many patients, and within that class combined estrogen-progestin formulations, estrogen-only regimens, and selective estrogen receptor modulators each present distinct safety profiles and prescribing contexts. Estrogen therapy itself splits across oral, topical, and transdermal delivery mechanisms, with transdermal options often preferred when mitigating systemic exposure and tailoring dose delivery.

Non-hormonal therapies form a complementary suite, including agents such as clonidine, gabapentin, and selective serotonin reuptake inhibitors, where molecule-specific tolerability and off-label usage patterns shape clinician choice. Within SSRIs, individual agents like fluoxetine, paroxetine, and sertraline exhibit differences in interaction potential and side-effect profiles that influence patient adherence and long-term management. Transitioning to distribution channels, clinics play a critical role in initiating care and managing follow-up, hospital pharmacies-both private and public-serve as important dispensing and formulary decision points, and online retailers, encompassing company websites and broader e-commerce platforms, are expanding access and altering consumer purchasing behavior.

Age group segmentation further refines strategic priorities: patients aged 40 to 50 typically present at or approaching perimenopause with different symptom trajectories and information needs than those aged 51 to 60 who are often in the acute menopausal transition, while those above 60 may prioritize long-term safety and comorbidity management. Integrating these segmentation layers enables targeted clinical messaging, formulary positioning, and tailored patient support interventions that align therapeutic attributes with channel strengths and patient expectations.

Regional dynamics and regulatory diversity across major geographies that shape treatment adoption, distribution strategies, and evidence generation priorities

Regional dynamics exert a powerful influence on regulatory approaches, prescribing norms, and distribution infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct strategic implications. In the Americas, established clinical guidelines and a mature payer environment create pathways for differentiated therapeutic positioning, while regional variations in access and coverage necessitate tailored market entry and patient support programs. Conversely, the Europe Middle East & Africa region includes a wide spectrum of regulatory regimes and payer models, requiring adaptive regulatory strategies and flexible pricing approaches to accommodate public health priorities and heterogeneous healthcare system capabilities.

In Asia-Pacific, demographic trends and rapid expansion of digital health platforms are reshaping patient engagement and distribution models, with e-commerce and telemedicine increasingly serving as gateways to care. Moreover, local manufacturing capabilities and regional supply chain hubs may present opportunities for cost-effective sourcing and faster scale-up of new formulations. Across all regions, cultural attitudes toward complementary therapies and hormonal treatment safety perceptions influence uptake, while region-specific clinical practice patterns affect how products are recommended and monitored.

To be successful across these geographies, stakeholders must adopt regionally differentiated strategies that respect regulatory nuance, local clinical practice, and distribution channel maturity, while leveraging global evidence generation to build cross-border credibility and optimize regional adoption.

Competitive landscape insights highlighting strategic differentiation through clinical rigor, supply chain agility, and distribution channel partnerships

Competitive positioning in the menopausal therapeutic space reflects a mix of legacy pharmaceutical companies, specialized biotech players, manufacturers of botanical and complementary products, and digitally native retailers and service providers. Established pharmaceutical organizations leverage deep clinical experience, broad regulatory capabilities, and integrated supply chains to maintain presence across hormonal and non-hormonal categories, while smaller innovators often differentiate through targeted mechanism-of-action research, improved tolerability profiles, or novel delivery technologies.

At the same time, manufacturers of complementary therapies drive consumer interest and often act as entry points for patients seeking self-managed alternatives, but they must navigate variability in clinical substantiation and regulatory frameworks. Distribution innovators, including hospital pharmacy systems and online platforms, influence visibility and access, creating opportunities for manufacturers to develop channel-specific value propositions and co-created patient engagement programs. Strategic collaborations between clinical research teams and commercial stakeholders are increasingly common, with successful companies aligning early-stage evidence plans to anticipated reimbursement and formulary discussions.

In summary, companies that combine rigorous clinical evidence, adaptive supply chain strategies, and channel-tailored commercialization plans are best positioned to navigate the complexity of this therapeutic area and to capture durable clinical and commercial relevance.

Strategic and operational imperatives for senior leadership to align clinical evidence, channel strategies, and supply resilience for sustainable competitive advantage

Industry leaders should prioritize an integrative strategy that aligns evidence generation, patient engagement, and supply chain resilience to capitalize on evolving clinical and commercial dynamics. First, invest in targeted clinical studies that address safety, tolerability, and patient-reported outcomes for specific delivery modalities and molecules, thereby strengthening formulary and clinician acceptance. Concurrently, develop tailored patient support programs that bridge clinic-initiated care and digital follow-up, enhancing adherence and long-term outcomes through education and symptom tracking tools.

Operationally, diversify sourcing and build supplier redundancy to mitigate tariff-related and geopolitical risks, while implementing greater transparency in total cost-to-serve calculations to inform pricing and channel strategies. Commercially, design channel-specific go-to-market models that leverage hospital pharmacy partnerships for formulary inclusion, clinic relationships for prescriber education, and online platforms for direct-to-consumer engagement. Execute value-based pricing pilots where appropriate and engage payers early with real-world evidence demonstrating comparative effectiveness and quality-of-life improvements.

Finally, cultivate cross-functional teams that link clinical development, regulatory affairs, manufacturing, and commercial leadership to accelerate time-to-value and ensure that scientific advances translate into accessible, patient-centered therapeutic options.

Robust mixed-methods research framework integrating clinician interviews, regulatory analysis, and supply chain validation to produce defensible strategic insights

The research approach underpinning this analysis combined multi-source qualitative and quantitative inputs, triangulating peer-reviewed clinical literature, regulatory pronouncements, supply chain documentation, and stakeholder interviews to build a comprehensive and balanced perspective. Primary research included structured interviews with clinicians, pharmacy directors, and supply chain leaders to surface real-world practice patterns, channel economics, and operational constraints. Secondary research synthesized authoritative clinical studies, guideline updates, and policy changes to contextualize therapeutic decisions and safety considerations.

Data synthesis emphasized cross-validation across sources to mitigate bias and ensure robustness; clinical findings were compared against prescribing patterns and distribution flows, while supplier and tariff impacts were assessed through procurement records and industry reporting. The methodology prioritized transparency in assumptions and clarity on data provenance, and where gaps were identified, recommended targeted primary studies to resolve uncertainties. Ethical considerations and patient privacy were central to the primary research design, with insights anonymized and aggregated to protect confidentiality.

Overall, this mixed-methods approach provides a defensible foundation for the strategic insights and recommendations presented, enabling stakeholders to act with confidence while identifying areas that warrant deeper, bespoke investigation.

Synthesis of therapeutic choices, operational resilience, and evidence priorities that together form a practical roadmap for sustainable stakeholder impact

In conclusion, managing menopausal hot flashes in the current era requires a multifaceted strategy that blends clinical evidence, patient-centric delivery, and resilient commercial operations. Therapeutic options span complementary botanicals, established hormonal regimens across multiple delivery systems, and a growing set of non-hormonal pharmacotherapies, each with distinct considerations for safety, adherence, and channel fit. Simultaneously, policy changes and trade dynamics have underscored the need for proactive supply chain planning and flexible sourcing strategies to preserve access and predictability.

Strategic success will favor organizations that align rigorous evidence generation with targeted patient engagement, channel-specific commercialization, and operational agility. By adopting these imperatives, stakeholders can better meet clinician and patient expectations, navigate regulatory complexity, and maintain competitive positioning. The synthesis provided here is intended as a practical roadmap that supports prioritized action, continued learning, and iterative refinement as new data and regulatory developments emerge.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Menopausal Hot Flashes Market, by Product Type

  • 8.1. Complementary Therapy
    • 8.1.1. Black Cohosh
    • 8.1.2. Dong Quai
    • 8.1.3. Isoflavones
  • 8.2. Hormonal Therapy
    • 8.2.1. Combined Estrogen-Progestin Therapy
    • 8.2.2. Estrogen Therapy
      • 8.2.2.1. Oral Estrogen
      • 8.2.2.2. Topical Estrogen
      • 8.2.2.3. Transdermal Estrogen
    • 8.2.3. Selective Estrogen Receptor Modulators
  • 8.3. Non-Hormonal Therapy
    • 8.3.1. Clonidine
    • 8.3.2. Gabapentin
    • 8.3.3. SSRIs
      • 8.3.3.1. Fluoxetine
      • 8.3.3.2. Paroxetine
      • 8.3.3.3. Sertraline

9. Menopausal Hot Flashes Market, by Distribution Channel

  • 9.1. Clinics
  • 9.2. Hospital Pharmacies
    • 9.2.1. Private Hospitals
    • 9.2.2. Public Hospitals
  • 9.3. Online Retailers
    • 9.3.1. Company Websites
    • 9.3.2. E-Commerce Platforms

10. Menopausal Hot Flashes Market, by Age Group

  • 10.1. 40 To 50
  • 10.2. 51 To 60
  • 10.3. Above 60

11. Menopausal Hot Flashes Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Menopausal Hot Flashes Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Menopausal Hot Flashes Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Menopausal Hot Flashes Market

15. China Menopausal Hot Flashes Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Astellas Pharma Inc.
  • 16.7. Bayer AG
  • 16.8. Besins Healthcare
  • 16.9. Cipla Ltd.
  • 16.10. Endoceutics Inc.
  • 16.11. Ferring International Center S.A.
  • 16.12. GlaxoSmithKline plc
  • 16.13. Hisamitsu Pharmaceutical Co., Ltd.
  • 16.14. Lupin Ltd.
  • 16.15. Millendo Therapeutics, Inc.
  • 16.16. Mithra Pharmaceuticals SA
  • 16.17. Novartis AG
  • 16.18. Novo Nordisk A/S
  • 16.19. Organon & Co.
  • 16.20. Pfizer Inc.
  • 16.21. Sun Pharmaceutical Industries Ltd.
  • 16.22. Teva Pharmaceutical Industries Ltd.
  • 16.23. Theramex Ltd.
  • 16.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENOPAUSAL HOT FLASHES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MENOPAUSAL HOT FLASHES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)